Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer

Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Thomas J. Herzog Oncologist 2002; 7(Suppl 5): 3-10 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the latest literature on the use of topotecan in recurrent ovarian cancer. Compare and contrast the efficacy and safety of topotecan with other agents used for the treatment of recurrent ovarian cancer Identify the toxicity profile of topotecan in recurrent ovarian cancer patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Sept. 24, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Sept. 24, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Current Perspectives in the Treatment of Ovarian Cancer: An Update on the Role of Topotecan